Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04371393
Other study ID # GCO 08-1078-0014
Secondary ID
Status Terminated
Phase Phase 3
First received
Last updated
Start date April 30, 2020
Est. completion date January 2, 2022

Study information

Verified date April 2022
Source Icahn School of Medicine at Mount Sinai
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The mortality rate in SARS-CoV-2-related severe ARDS is high despite treatment with antivirals, glucocorticoids, immunoglobulins, and ventilation. Preclinical and clinical evidence indicate that MSCs migrate to the lung and respond to the pro-inflammatory lung environment by releasing anti-inflammatory factors reducing the proliferation of pro-inflammatory cytokines while modulating regulatory T cells and macrophages to promote resolution of inflammation. Therefore, MSCs may have the potential to increase survival in management of COVID-19 induced ARDS. The primary objective of this phase 3 trial is to evaluate the efficacy and safety of the addition of the mesenchymal stromal cell (MSC) remestemcel-L plus standard of care compared to placebo plus standard of care in patients with acute respiratory distress syndrome (ARDS) due to SARS-CoV-2. The secondary objective is to assess the impact of MSCs on inflammatory biomarkers.


Description:

This will be a randomized (1:1 ratio), double blind, parallel design, placebo controlled trial. Randomization will be stratified by clinical center and by moderate versus severe ARDS. The study is designed to have three interim analyses for stopping accrual early for efficacy and futility when 30%, 45% and 60% of the 300 patients have reached the primary endpoint using Bayesian predictive probabilities. Patients will be randomized in a 1:1 allocation to intravenous infusion of MSCs (remestemcel-L) plus standard of care versus placebo plus standard of care for the treatment of COVID-19 related ARDS: - Group 1: 2x10^6 MSC/kg of body weight plus standard of care, administered twice during the first week, with the second infusion at 4 days following the first infusion (± 1 day) - Group 2: Placebo (Plasma-Lyte) plus standard of care, administered twice during the first week, with the second infusion at 4 days following the first infusion (± 1 day) (control) MSCs and placebo will initially be administered intravenously in the dose defined above at randomization. The rate of infusion may be tailored to the patient's respiratory status and fluid status, but the duration of infusion should not exceed 60 minutes. Patients will be followed for 90 days post randomization, with assessment of pulmonary symptoms at 6 and 12 months.


Recruitment information / eligibility

Status Terminated
Enrollment 223
Est. completion date January 2, 2022
Est. primary completion date January 14, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria - 18 years or older - Patient has SARS-CoV-2 (COVID-19) confirmed by real-time reverse transcription polymerase chain reaction (RT-PCR) assay or other diagnostic test - Patient requiring mechanical ventilatory support with moderate to severe ARDS as determined by the following criteria (adapted from the Berlin criteria) - Bilateral opacities must be present on a chest radiograph or computerized tomographic (CT) scan. These opacities are not fully explained by pleural effusions, lobar collapse, lung collapse, or pulmonary nodules. - Respiratory failure not fully explained by cardiac failure or fluid overload. - Moderate to severe impairment of oxygenation must be present, as defined by the ratio of arterial oxygen tension to fraction of inspired oxygen (PaO2/FiO2). The severity of the hypoxemia defines the severity of the ARDS: - Moderate ARDS: PaO2/FiO2 >100 mmHg and =200 mmHg, on ventilator settings that include PEEP =5 cm H2O OR - Severe ARDS: PaO2/FiO2 =100 mmHg on ventilator settings that include PEEP =5 cm H2O - High sensitivity C-Reactive Protein (hs-CRP) or CRP serum level >4.0 mg/dL - Acute Physiologic and Chronic Health Evaluation (APACHE IV) score >5 - Creatinine clearance of = 30 mL/minute OR a creatinine clearance of 20-29 mL/minute with urine output of =0.3 mLs/kg/hour over the last 8 hours or =500 mLs over the last 24 hours - The patient or his/her legally authorized representative (LAR) is able to provide informed consent Exclusion Criteria - Currently receiving extracorporeal membrane oxygenation (ECMO) or high frequency oscillatory ventilation (HFOV) - Females who are pregnant or lactating - Patients with established positive bacterial blood cultures prior to enrollment or suspicion of superimposed bacterial pneumonia - Patients with BMI >55 - Patients with untreated HIV infection - Patients with malignancy who are within 12 months of active treatment with any chemotherapy, radiation or immunotherapy. - Patients who have been intubated for more than 72 hours in total at the time of randomization - Creatinine clearance less than 20 mL/minute or receiving renal replacement therapy - LFTs (isolated ALT or AST) > 8x upper limit of normal or > 5x upper limit of normal in the setting of other liver function abnormalities (i.e., total bilirubin = 2x upper limit of normal) - Known hypersensitivity to DMSO or to porcine or bovine proteins - History of prior respiratory disease with requirement for supplemental oxygen - Any end-stage organ disease which in the opinion of the investigator may possibly affect the safety of remestemcel-L treatment - Receiving an investigational cellular therapy agent

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Remestemcel-L
administered twice during the first week, with the second infusion at 4 days following the first injection (± 1 day)
Drug:
Placebo
administered twice during the first week, with second infusion at 4 days following the first injection (± 1 day)

Locations

Country Name City State
United States University of Michigan Ann Arbor Michigan
United States Emory University Atlanta Georgia
United States University of Maryland Baltimore Maryland
United States Brigham and Women's Hospital Boston Massachusetts
United States University of Virginia Charlottesville Virginia
United States Cleveland Clinic Foundation Cleveland Ohio
United States Duke University Medical Center Durham North Carolina
United States Lutheran Hospital Fort Wayne Indiana
United States Dignity Health Gilbert Arizona
United States Houston Methodist Hospital Houston Texas
United States Dartmouth-Hitchcock Lebanon New Hampshire
United States University of Southern California Los Angeles California
United States Ochsner Clinic New Orleans Louisiana
United States Mount Sinai Health New York New York
United States New York University Langone Health New York New York
United States Northwell Health New York New York
United States University of Pennsylvania Health System Philadelphia Pennsylvania
United States Baylor, Smith & White Plano Texas
United States Maine Medical Center Portland Maine
United States WakeMed Raleigh North Carolina
United States Stanford University Stanford California

Sponsors (3)

Lead Sponsor Collaborator
Icahn School of Medicine at Mount Sinai Mesoblast, Inc., National Heart, Lung, and Blood Institute (NHLBI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of all-cause mortality Number of all-cause mortality within 30 days of randomization. 30 days
Secondary Number of days alive off mechanical ventilatory support Number of days alive off mechanical ventilatory support calculated as the number of days, within the 60 days window, that patients were alive and free of mechanical ventilatory support. 60 days
Secondary Number of adverse events Safety analyses will be assessed by adverse event rates calculated as the ratio of the total number of events over 30 days divided by total patient-time at risk for the specific event from randomization. 30 days
Secondary Number of participants alive at day 7 7 days
Secondary Number of participants alive at day 14 14 days
Secondary Number of participants alive at day 60 60 days
Secondary Number of participants alive at day 90 90 days
Secondary Number of participants alive at 12 Months 12 Months
Secondary Number of participants with resolution and/or improvement of ARDS The number and percent of patients with resolution and/or improvement of ARDS at day 7 7 days
Secondary Number of participants with resolution and/or improvement of ARDS The number and percent of patients with resolution and/or improvement of ARDS at day 14 14 days
Secondary Number of participants with resolution and/or improvement of ARDS The number and percent of patients with resolution and/or improvement of ARDS at day 21 21 days
Secondary Number of participants with resolution and/or improvement of ARDS The number and percent of patients with resolution and/or improvement of ARDS at day 30 30 days
Secondary Severity of ARDS severity of ARDS according to Berlin Criteria at days 7 post-randomization Change from baseline of the severity of ARDS according to Berlin Criteria at days 7, 14, 21 and 30 post-randomization will be compared between treatment groups using a Cochran-Mantel-Haenszel test stratified by baseline severity. baseline and 7 days
Secondary Severity of ARDS severity of ARDS according to Berlin Criteria at days 14 post-randomization Change from baseline of the severity of ARDS according to Berlin Criteria at days 7, 14, 21 and 30 post-randomization will be compared between treatment groups using a Cochran-Mantel-Haenszel test stratified by baseline severity. baseline and 14 days
Secondary Severity of ARDS severity of ARDS according to Berlin Criteria at days 21 post-randomization Change from baseline of the severity of ARDS according to Berlin Criteria at days 7, 14, 21 and 30 post-randomization will be compared between treatment groups using a Cochran-Mantel-Haenszel test stratified by baseline severity. baseline and 21 days
Secondary Severity of ARDS severity of ARDS according to Berlin Criteria at days 30 post-randomization Change from baseline of the severity of ARDS according to Berlin Criteria at days 7, 14, 21 and 30 post-randomization will be compared between treatment groups using a Cochran-Mantel-Haenszel test stratified by baseline severity. baseline and 30 days
Secondary Length of stay Hospital length of stay 12 months
Secondary Readmissions number of readmission 12 months
Secondary Length of Stay in Intensive Care Unit 12 months
Secondary Clinical Improvement Scale Change from baseline in Clinical Improvement Scale at day 7. Clinical Improvement Scale full scale from 1 to 7, with higher score indicating more clinical improvement. 7 days
Secondary Clinical Improvement Scale Change from baseline in Clinical Improvement Scale at day 14. Full scale from 1 to 7, with higher score indicating more clinical improvement. 14 days
Secondary Clinical Improvement Scale Change from baseline in Clinical Improvement Scale at day 21. Clinical Improvement Scale full scale from 1 to 7, with higher score indicating more clinical improvement. 21 days
Secondary Clinical Improvement Scale Change from baseline in Clinical Improvement Scale at day 30. Clinical Improvement Scale full scale from 1 to 7, with higher score indicating more clinical improvement. 30 days
Secondary Change in plasma hs-CRP concentration Changes from baseline in plasma hs-CRP concentration at days 7 baseline and 7 days
Secondary Change in plasma hs-CRP concentration Changes from baseline in plasma hs-CRP concentration at days 14 baseline and 14 days
Secondary Change in plasma hs-CRP concentration Changes from baseline in plasma hs-CRP concentration at days 21 baseline and 21 days
Secondary Change in serum hs-CRP concentration Changes from baseline in serum hs-CRP concentration at days 30 baseline and 30 days
Secondary Change in IL-6 inflammatory marker level Changes from baseline in IL-6 inflammatory marker level at 7 days baseline and 7 days
Secondary Change in IL-6 inflammatory marker level Changes from baseline in IL-6 inflammatory marker level at 14 days baseline and 14 days
Secondary Change in IL-6 inflammatory marker level Changes from baseline in IL-6 inflammatory marker level at 21 days baseline and 21 days
Secondary Change in IL-6 inflammatory marker level Changes from baseline in IL-6 inflammatory marker level at 30 days baseline and 30 days
Secondary Change in IL-8 inflammatory marker level Changes from baseline in IL-6 inflammatory marker level at 7 days baseline and 7 days
Secondary Change in IL-8 inflammatory marker level Changes from baseline in IL-6 inflammatory marker level at 21 days baseline and 21 days
Secondary Change in IL-8 inflammatory marker level Changes from baseline in IL-6 inflammatory marker level at 14 days baseline and 14 days
Secondary Change in IL-8 inflammatory marker level Changes from baseline in IL-6 inflammatory marker level at 30 days baseline and 30 days
Secondary Change in TNF-alpha inflammatory marker level Changes from baseline in TNF-alpha inflammatory marker level at 7 days baseline and 7 days
Secondary Change in TNF-alpha inflammatory marker level Changes from baseline in TNF-alpha inflammatory marker level at 14 days baseline and 14 days
Secondary Change in TNF-alpha inflammatory marker level Changes from baseline in TNF-alpha inflammatory marker level at 21 days baseline and 21 days
Secondary Change in TNF-alpha inflammatory marker level Changes from baseline in TNF-alpha inflammatory marker level at 30 days baseline and 30 days
Secondary Pulmonary symptoms including the presence of emphysema, COPD, asthma, pulmonary fibrosis, other pulmonary disease, and the need for respiratory support will be reported by randomization 6 months
Secondary Pulmonary symptoms including the presence of emphysema, COPD, asthma, pulmonary fibrosis, other pulmonary disease, and the need for respiratory support will be reported by randomization 12 months
See also
  Status Clinical Trial Phase
Completed NCT04384445 - Zofin (Organicell Flow) for Patients With COVID-19 Phase 1/Phase 2
Recruiting NCT05535543 - Change in the Phase III Slope of the Volumetric Capnography by Prone Positioning in Acute Respiratory Distress Syndrome
Completed NCT04695392 - Restore Resilience in Critically Ill Children N/A
Terminated NCT04972318 - Two Different Ventilatory Strategies in Acute Respiratory Distress Syndrome Due to Community-acquired Pneumonia N/A
Completed NCT04534569 - Expert Panel Statement for the Respiratory Management of COVID-19 Related Acute Respiratory Failure (C-ARF)
Completed NCT04078984 - Driving Pressure as a Predictor of Mechanical Ventilation Weaning Time on Post-ARDS Patients in Pressure Support Ventilation.
Completed NCT04451291 - Study of Decidual Stromal Cells to Treat COVID-19 Respiratory Failure N/A
Not yet recruiting NCT06254313 - The Role of Cxcr4Hi neutrOPhils in InflueNza
Not yet recruiting NCT04798716 - The Use of Exosomes for the Treatment of Acute Respiratory Distress Syndrome or Novel Coronavirus Pneumonia Caused by COVID-19 Phase 1/Phase 2
Withdrawn NCT04909879 - Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Non-COVID-19 Acute Respiratory Distress Syndrome Phase 2
Not yet recruiting NCT02881385 - Effects on Respiratory Patterns and Patient-ventilator Synchrony Using Pressure Support Ventilation N/A
Terminated NCT02867228 - Noninvasive Estimation of Work of Breathing N/A
Completed NCT02545621 - A Role for RAGE/TXNIP/Inflammasome Axis in Alveolar Macrophage Activation During ARDS (RIAMA): a Proof-of-concept Clinical Study
Withdrawn NCT02253667 - Palliative Use of High-flow Oxygen Nasal Cannula in End-of-life Lung Disease Patients N/A
Completed NCT02232841 - Electrical Impedance Imaging of Patients on Mechanical Ventilation N/A
Withdrawn NCT01927237 - Pulmonary Vascular Effects of Respiratory Rate & Carbon Dioxide N/A
Completed NCT02889770 - Dead Space Monitoring With Volumetric Capnography in ARDS Patients N/A
Completed NCT01504893 - Very Low Tidal Volume vs Conventional Ventilatory Strategy for One-lung Ventilation in Thoracic Anesthesia N/A
Completed NCT01680783 - Non-Invasive Ventilation Via a Helmet Device for Patients Respiratory Failure N/A
Completed NCT02814994 - Respiratory System Compliance Guided VT in Moderate to Severe ARDS Patients N/A